0000920465-19-000172.txt : 20191206 0000920465-19-000172.hdr.sgml : 20191206 20191206170151 ACCESSION NUMBER: 0000920465-19-000172 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191202 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities FILED AS OF DATE: 20191206 DATE AS OF CHANGE: 20191206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 191273716 BUSINESS ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-207-4264 MAIL ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 a20198-k06dec19.htm 8-K Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report: December 2, 2019
(Date of earliest event reported)

LA JOLLA PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
Commission File Number: 1-36282
 
 
 
 
California
 
 
33-0361285
(State or other jurisdiction of
incorporation or organization)
 
 
(I.R.S. Employer
Identification No.)

4550 Towne Centre Court, San Diego, California 92121
(Address of principal executive offices, including zip code)

(858) 207-4264
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, Par Value $0.0001
per share
 
LJPC
 
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company o
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o





ITEM 2.05
Costs Associated with Exit or Disposal Activities.

On December 2, 2019, the Board of Directors of La Jolla Pharmaceutical Company (the “Company”) approved a restructuring plan that reduced the Company’s headcount. The restructuring does not result in any reductions in headcount in the Company’s commercial organization supporting GIAPREZATM (angiotensin II). The Company estimates that it will incur expenses of approximately $6.0 million related to the restructuring, which will be incurred in the fourth quarter of 2019 and consist of one-time termination benefits to the affected employees, including severance and healthcare benefits.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
LA JOLLA PHARMACEUTICAL COMPANY
 
 
 
 
Date:
December 6, 2019
By:
/s/ Dennis Mulroy
 
 
 
Dennis Mulroy
 
 
 
Chief Financial Officer